Brief: Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
09/07/2024 14:19
July 9 (Reuters) - Myriad Genetics Inc MYGN.O :
* MYRIAD GENETICS ANNOUNCES SECOND FOUNDATIONAL PATENT
GRANTED FOR
MOLECULAR RESIDUAL DISEASE (MRD) WITH EARLY PRIORITY DATE
Source text for Eikon: ID:nGNX1NxYTS
Further company coverage: MYGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Myriad Genetics
See all newsUS STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
US STOCKS ON THE MOVE-Hilton, MSCI, Tradeweb, Eli Lilly
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple